Global Radiotheranostics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Radiotheranostics Market is presumed to reach the market size of nearly USD 23.97 Billion by 2032 from USD 8.03 Billion in 2023 with a CAGR of 12.92% under the study period 2024 - 2032.

Radiotheranostics is an emerging field that combines diagnostic imaging and targeted radiotherapy for personalized cancer treatment. It involves the development and use of radiopharmaceuticals that can both diagnose and treat cancer by administering therapeutic doses of radiation to tumor cells while sparing healthy tissue. This approach targets specific molecular markers or receptors expressed by cancer cells, enabling precise localization and treatment of tumors while monitoring treatment response through imaging methods, including positron emission tomography (PET) or single-photon emission computed tomography (SPECT).

MARKET DYNAMICS

The increasing prevalence of cancer worldwide has spurred the demand for more effective and personalized treatment options, leading to a growing interest in radiotheranostic approaches. Radiotheranostics, which combines therapeutic and diagnostic capabilities in a single agent, offers a promising solution for targeted cancer therapy and accurate imaging for treatment planning and monitoring. Furthermore, advancements in radiopharmaceuticals and imaging technologies have enhanced the efficacy and safety of radiotheranostic procedures, encouraging their adoption by healthcare providers and patients. Additionally, the rising investments in research and development by pharmaceutical companies and academic institutions fuel the innovation and commercialization of novel radiotheranostic agents and imaging modalities.

Moreover, favorable government initiatives and regulatory support aimed at promoting precision medicine and improving cancer care are further stimulating the growth of the radiotheranostics market. Additionally, the increasing awareness among healthcare practitioners and patients about the benefits of radiotheranostics in improving treatment outcomes and reducing side effects contributes to market expansion. However, the evolving regulatory landscape and pricing pressures may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of radiotheranostics. The growth and trends of radiotheranostics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the radiotheranostics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Radioisotope

Iodine-131
Iodine-123
Gallium-68
Lutetium-177
18F With Y-90
Others

By Approach

Targeted Therapeutic
Targeted Diagnostic

By Application

Oncology (Thyroid Cancer, Neuroendocrine Tumors, Hepatocellular Carcinoma, Prostate Cancer, Others)
Non-Oncology (Neurological Disorders, Arthritis, Others)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Radiotheranostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Radiotheranostics market include Progenics Pharmaceuticals, Inc. (Lantheus), Telix Pharmaceuticals Limited, ITM Radiopharma, Life Molecular Imaging., RadioMedix, IsoTherapeutics Group, LLC, Q BioMed Inc., Nordic Nanovector ASA, Novartis AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114260

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. RADIOTHERANOSTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Radioisotope
- 3.7.2 Market Attractiveness Analysis By Approach
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL RADIOTHERANOSTICS MARKET ANALYSIS BY RADIOISOTOPE

5.1. Overview By Radioisotope
5.2. Historical and Forecast Data
5.3. Analysis By Radioisotope
5.4. Iodine-131 Historic and Forecast Sales By Regions
5.5. Iodine-123 Historic and Forecast Sales By Regions
5.6. Gallium-68 Historic and Forecast Sales By Regions
5.7. Lutetium-177 Historic and Forecast Sales By Regions
5.8. 18F with Y-90 Historic and Forecast Sales By Regions
5.9. Others Historic and Forecast Sales By Regions

6. GLOBAL RADIOTHERANOSTICS MARKET ANALYSIS BY APPROACH

6.1. Overview By Approach
6.2. Historical and Forecast Data
6.3. Analysis By Approach
6.4. Targeted Therapeutic Historic and Forecast Sales By Regions
6.5. Targeted Diagnostic Historic and Forecast Sales By Regions

7. GLOBAL RADIOTHERANOSTICS MARKET ANALYSIS BY APPLICATION

7.1. Overview By Application
7.2. Historical and Forecast Data
7.3. Analysis By Application
7.4. Oncology (Thyroid Cancer, Neuroendocrine Tumors, Hepatocellular Carcinoma, Prostate Cancer, Others) Historic and Forecast Sales By Regions
7.5. Non-oncology (Neurological Disorders, Arthritis, Others) Historic and Forecast Sales By Regions

8. GLOBAL RADIOTHERANOSTICS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE RADIOTHERANOSTICS COMPANIES

9.1. Radiotheranostics Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF RADIOTHERANOSTICS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Progenics Pharmaceuticals Inc. (Lantheus)
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Telix Pharmaceuticals Limited
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. ITM Radiopharma
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Life Molecular Imaging.
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. RadioMedix
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. IsoTherapeutics Group LLC
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Q BioMed Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Nordic Nanovector ASA
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Novartis AG
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies